TRPV2 and melanoma: TRPV2 activation also promotes bortezomib-induced cell death in RPMI and U166 melanoma-derived cell lines [231], suggesting that combinatorial treatments using TRPV2 activators and chemotherapeutics may represent an effective strategy to improve cancer therapy.